Pioneering precision medicine for autoimmune diseases
True scalability in response prediction and patient stratification
Utilizing epiproteomic analysis to uncover hidden insights
Epiproteomics studies the changes that occur to the proteins after their synthesis and folding, including Post Translational Modifications (PTMs) that regulate their activity and function
Comprehensive View
Better understanding of disease mechanisms
Dynamics analysis
PTMs capture the regulated proteome
Direct correlation
At the heart of most autoimmune diseases
Mechanism understanding
Explainable, biologically-relevant insights
Comprehensive View
Better understanding of disease mechanisms
Dynamics analysis
PTMs capture the regulated proteome
Direct correlation
At the heart of most autoimmune diseases
Mechanism understanding
Explainable, biologically-relevant insights
Broad exploration. Accurate predictions. True scalability.
Unbiased approach
Exploring a broad range of the PTM landscape by integrating chemical knowledge, statistics, and advanced algorithms to address the computational burden while ensuring no biologically-relevant factors are overlooked
Explainable insights
Harnessing explainable AI, and
clinically-oriented algorithms, to provide high-impact recommendations
Leveraging existing data
Leveraging standard mass-spectrometry data and revisiting existing analyses using continuously evolving AI models without the need for chemical enrichment for unveiling previously concealed information.
Partner with us
Enable precision medicine
- Treatment selection
- Early assessment of response
- Disease monitoring
Boost drug development
- Biomarker discovery
- Patient selection
- Clinical trials enrichment
Founding Team
Ronel Veksler, MD, PhD
Ronel holds an MD-PhD from Ben-Gurion University and a BSc in Electrical Engineering from the Technion, and is the recipient of multiple awards for academic excellence.His experience spans across medicine, research, product management and algorithm development.After practicing medicine for several years, Ronel joined C2i-Genomics, where he served as the senior director of product, before co-founding PromiseBio.With his interdisciplinary experience, Ronel is connecting the dots at the intersection of cutting-edge science, medicine, and technology, to promote precision medicine for patients with complex diseases.
Assaf Kacen
Assaf brings extensive knowledge in bioinformatics, systems biology, and data science. He earned his PhD from the Weizmann Institute of Science, focusing on immunology, especially in epiproteomics, and a BSc in Computer Engineering from Ben-Gurion University and an MBA from Richman University.Before his Ph.D. studies, Assaf served as the COO of Evogene ($EVGN), managing multidisciplinary teams in complex R&D projects and scaling operations.His expertise is in bridging the gap between scientific research, technological innovation, and practical applications, combining vast experience in computational engineering, algorithms, and biology.
Yifat Merbl, PhD
Prof. Merbl is an Associate Professor at the Weizmann Institute of Science.Working at the meeting point between biochemistry, proteomics, and immunology, Prof. Merbl addresses basic and translational research questions in immunity. Her lab focuses on uncovering regulatory mechanisms of the epiproteome, by studying changes in protein post-translational modifications and protein degradation. Prof. Merbl’s lab developed proprietary platform technologies that enable the analysis of biological samples in different disease settings, enabling discoveries that set the basis for translational research for biomarker and target discovery and novel therapeutic opportunities. Prof. Merbl earned her PhD in Systems Biology from Harvard Medical School, MSc in Immunology from the Weizmann Institute and BSc in Computational Biology from Bar-Ilan University (summa cum laude), and is the recipient of numerous awards.
